

UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2021 to February 28, 2021

CORPORATE MONTHLY OPERATING REPORT

REQUIRED DOCUMENTS	Form No.	Document Attached	Explanation Attached
Schedule of Cash Receipts and Disbursements	MOR-1a	Yes	-
Bank Account Balances	MOR-1b	Yes	-
Consolidated Statement of Operations	MOR-2	Yes	-
Consolidated Balance Sheet	MOR-3	Yes	-
Schedule of Post-petition Taxes	MOR-4	-	Yes
Schedule of Payments to Insiders and Restructuring Professional Fees	MOR-5	Yes	-
Debtor Questionnaire	MOR-6	Yes	-

This Monthly Operating Report has been prepared solely for the purposes of complying with the monthly reporting requirements applicable in these chapter 11 cases and is in a format that the Debtors believe is acceptable to the United States Trustee. The financial information contained herein is limited in scope and covers a limited time period. Moreover, such information is preliminary and unaudited, and is not prepared in accordance with GAAP.

I declare under penalty of perjury that this report and the attached documents are true and correct to the best of my knowledge and belief.

*J. R. Lowe*

3/19/2021

Signature of Authorized Individual\*

Date

*Jon Lowe*

3/19/2021

Printed Name of Authorized Individual

Date

\*Authorized individual must be an officer, director or shareholder if debtor is a corporation.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2021 to February 28, 2021

**SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS (\$)**

Case No.	Debtor Entity Name:	Net Receipts <sup>2</sup>	Net Disbursements <sup>1</sup>
087-19-23648	PURDUE PHARMA INC.	\$ 8,002	\$ 266,667
087-19-23649	PURDUE PHARMA L.P.	80,224,654	65,825,683
087-19-23650	PURDUE TRANSDERMAL TECHNOLOGIES, L.P.	-	-
087-19-23651	PURDUE PHARMA MANUFACTURING L.P.	-	-
087-19-23652	PURDUE PHARMACEUTICALS L.P.	-	10,210,251
087-19-23653	IMBRIUM THERAPEUTICS L.P.	-	1,891,220
087-19-23654	ADLON THERAPEUTICS L.P.	44,979	2,863,566
087-19-23655	GREENFIELD BIO VENTURES L.P.	-	-
087-19-23656	SEVEN SEAS HILL CORP.	-	-
087-19-23657	OPHIR GREEN CORP.	-	-
087-19-23658	PURDUE PHARMA OF PUERTO RICO	-	880
087-19-23659	AVRIO HEALTH L.P.	13,867	4,505,669
087-19-23660	PURDUE PHARMACEUTICAL PRODUCTS L.P.	-	9,176
087-19-23661	PURDUE NEUROSCIENCE COMPANY	-	-
087-19-23662	NAYATT COVE LIFESCIENCE INC.	-	-
087-19-23663	BUTTON LAND L.P.	-	-
087-19-23664	PAUL LAND INC.	-	-
087-19-23665	QUIDNICK LAND L.P.	-	-
087-19-23666	RHODES ASSOCIATES L.P.	-	-
087-19-23667	RHODES PHARMACEUTICALS L.P.	19,109,901	23,777,484
087-19-23668	RHODES TECHNOLOGIES	5,880,196	900,800
087-19-23669	UDF LP	-	-
087-19-23670	SVC PHARMA LP	-	-
087-19-23671	SVC PHARMA INC.	-	-
<b>Totals:</b>		<b>\$ 105,281,599</b>	<b>\$ 110,251,395</b>

**Footnotes**

1) The Net Disbursements exclude intercompany transactions among Debtors

2) The Net Receipts exclude intercompany transactions among Debtors

In re: PURDUE PHARMA L.P., et al.,  
DebtorsCase No.: 19-23649 (RDD)  
February 28, 2021

## BANK ACCOUNT BALANCES (\$)

Debtor	Bank	Account Number	Description	Balance as of Month End
Purdue Pharma L.P.	American Express National Bank (Restricted Cash)	xxxxxxxx65041	CD	\$ 750,229
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx2400	Escrow	10,866,191
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx3900	Escrow	-
Purdue Pharma L.P.	East West Bank	xxxxxxxx9773	LOC/Collateral	10,006,088
Purdue Pharma L.P.	East West Bank	xxxxxxxx9808	LOC/Collateral	5,252,146
Purdue Pharma L.P.	East West Bank	xxxxxxxx9836	LOC/Collateral	1,661,020
Purdue Pharma L.P.	East West Bank	xxxxxxxx9136	Money Market Account	200,023,248
Purdue Pharma L.P.	Metropolitan Commercial Bank	xxxxxxxx4813	Money Market Account	100,296,603
Purdue Pharma L.P.	Bank of Oklahoma	xxxxxx8720	Money Market Account	100,203,401
Purdue Pharma L.P.	JPMorgan/Dreyfus Funds #761	xxxx7720	Money Market Fund	-
Purdue Pharma L.P.	Goldman Sachs #520	xxxx8266	Money Market Fund	53,826,614
Purdue Pharma L.P.	Goldman Sachs #506	xxxx0462	Money Market Fund	510,595,207
Purdue Pharma L.P.	JP Morgan Chase	xxxxx5837	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxxxx9129	Operating	17,745,533
Purdue Pharma L.P.	JP Morgan Chase	xxxxxxxxxx8509	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx8921	Operating	-
Purdue Pharma L.P.	JP Morgan Chase	xxxxx2890	Operating	-
Purdue Pharma L.P.	East West Bank	xxxxxxxx9388	ERISA	237,334
Purdue Pharma L.P.	Bank of Oklahoma	xxxxxx6017	Trust	15,282,510
Purdue Pharma L.P.	East West Bank	xxxxxxxx9549	Operating	350,663
Purdue Pharma L.P.	East West Bank (Restricted Cash)	xxxxxxxx9304	Restricted Account	-
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx1100	Trust	10,273,954
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx6600	Trust	59,183,976
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxxxx6077	Trust	0
Purdue Pharma L.P.	Metropolitan Commercial Bank (Restricted Cash)	xxxxxxxx4767	Trust	29,159,013
Purdue Pharma L.P.	Wells Fargo (Restricted Cash)	xxxx0300	Trust	10,392,665
Purdue Pharma L.P.	Bank of Oklahoma	xxxxxx4018	Trust	25,106,380
Purdue Pharma Inc.	East West Bank	xxxxxxxx9213	Operating	1,250,265
Purdue Pharma Inc.	JP Morgan Chase	xxxxx2866	Operating	-
Purdue Pharmaceuticals L.P.	Wells Fargo (Restricted Cash)	xxxx5300	Trust	125,979
Imbrrium Therapeutics L.P.	JP Morgan Chase	xxxxx1191	Operating	-
Imbrrium Therapeutics L.P.	East West Bank	xxxxxxxx9241	Operating	-
Adlon Therapeutics L.P.	East West Bank	xxxxxxxx9248	Operating	-
Adlon Therapeutics L.P.	JP Morgan Chase	xxxxx5999	Operating	-
Greenfield BioVentures L.P.	JP Morgan Chase	xxxxx1118	Operating	-
Greenfield BioVentures L.P.	East West Bank	xxxxxxxx9234	Operating	-
Purdue Pharma of Puerto Rico	East West Bank	xxxxxxxx9185	Operating	-
Purdue Pharma of Puerto Rico	JP Morgan Chase	xxxxx5485	Operating	-
Avrio Health L.P.	East West Bank	xxxxxxxx9199	Operating	-
Avrio Health L.P.	JP Morgan Chase	xxxxx9278	Operating	-
Purdue Neuroscience Company	East West Bank	xxxxxxxx9227	Operating	-
Purdue Neuroscience Company	JP Morgan Chase	xxxxx6535	Operating	-
Nayatt Cove Lifescience Inc.	JP Morgan Chase	xxxxx8162	Operating	-
Nayatt Cove Lifescience Inc.	East West Bank	xxxxxxxx9220	Operating	-
Button Land L.P.	East West Bank	xxxxxxxx9297	Operating	-
Button Land L.P.	JP Morgan Chase	xxxxx1875	Operating	-
Paul Land Inc.	East West Bank	xxxxxxxx9290	Operating	-
Paul Land Inc.	JP Morgan Chase	xxxxx1859	Operating	-
Quidnick Land L.P.	JP Morgan Chase	xxxxx1891	Operating	-
Quidnick Land L.P.	East West Bank	xxxxxxxx9304	Operating	-
Rhodes Pharmaceuticals L.P.	JPMorgan/Dreyfus Funds #761	xxxx3154	Money Market Fund	-
Rhodes Pharmaceuticals L.P.	East West Bank	xxxxxxxx9269	Operating	-
Rhodes Pharmaceuticals L.P.	JP Morgan Chase	xxxxx6220	Operating	-
Rhodes Technologies	JPMorgan/Dreyfus Funds #761	xxxx3153	Money Market Fund	-

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
February 28, 2021

BANK ACCOUNT BALANCES (\$)

Debtor	Bank	Account Number	Description	Balance as of Month End
Rhodes Technologies	JP Morgan Chase	xxxxxxxxx2509	Operating	-
Rhodes Technologies	JP Morgan Chase	xxxxxx6362	Operating	-
Rhodes Technologies	East West Bank	xxxxxx9262	Operating	-
SVC Pharma LP	JP Morgan Chase	xxxxx9855	Operating	-
SVC Pharma LP	East West Bank	xxxxxx9276	Operating	-
SVC Pharma Inc.	JP Morgan Chase	xxxxx9863	Operating	-
SVC Pharma Inc.	East West Bank	xxxxxx9283	Operating	-
<b>Total</b>				<b>\$ 1,162,589,019</b>

In re: PURDUE PHARMA L.P., et al.  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2021 to February 28, 2021

CONSOLIDATED STATEMENT OF OPERATIONS (\$M)<sup>1,2</sup>

Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc

	Current Month	2021 Year to Date	2019 Cumulative Filing to Date <sup>3</sup>
Net Sales	\$ 66	\$ 137	\$ 1,337
Cost of Goods Sold	(9)	(32)	(341)
Gross Profit	57	105	995
Sales and Promotion	(6)	(16)	(162)
Research and Development	(5)	(9)	(123)
General and Administrative	(5)	(10)	(142)
Legal Fees - Ordinary Course	(0)	(1)	(16)
Medical Affairs	(2)	(5)	(53)
Milestones & Alliances	-	-	(8)
Health Care Reform Fee	-	(1)	(15)
Other US	(0)	(0)	(3)
Incentive Bonus	(3)	(6)	(50)
Total Operating Expenses	(21)	(49)	(573)
Operating Profit	36	56	423
Legal Fees - Non-Recurring	(26)	(49)	(523)
Other <sup>4</sup>	(14)	(14)	(63)
Total Non-Operating Expenses	(40)	(63)	(586)
Profit / (Loss) <sup>5</sup>	\$ (4)	\$ (7)	\$ (163)

**Footnotes**

1) The numbers reflected in the Consolidated Statement of Operations are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

4) Includes non-cash write downs of \$62M related to Rhodes Technologies assets and a fixed asset impairment of \$8M, offset by a gain recorded on an investment of \$32M.

5) The debtors historically updated contingencies as part of their year-end review with their auditors, Ernst and Young. That process is ongoing for year ended December 31st, 2020 and as of this reporting, the Debtors have not completed their assessment of the adjustments required to accruals for settlements entered into during 2020, other claims made against the Debtors or settlement discussions that are ongoing. The Debtors, note however, that they are in active settlement discussions with various creditors to settle outstanding claims and will incorporate any settlements as appropriate when the accruals are updated. Refer to separate disclosure on Liabilities Subject to Compromise and Contingencies.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2021 to February 28, 2021

**PURDUE PHARMA, INC. STATEMENT OF OPERATIONS (\$000)<sup>1,2</sup>**

	<b>Current Month</b>	<b>2021 Year to Date</b>	<b>2019 Cumulative Filing to Date<sup>3</sup></b>
Management Fee Income	\$ 29	\$ 58	523
General and Administrative Expenses	-	-	(66)
Operating Income	29	58	457
		-	
Income from Unconsolidated Associated Companies	(102)	(54)	(1,221)
Total Other Income	(102)	(54)	(1,221)
		-	
Pre-Tax Income	(73)	4	(764)
		-	
Income Tax Provision	20	(1)	192
		-	
Net Income	\$ (53)	\$ 3	\$ (572)

**Footnotes**

1) The numbers reflected in the Statement of Operations are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.

3) Cumulative results for 2019 are beginning September 1, 2019 as operating results for the partial month from the filing date of September 15, 2019 to September 30, 2019 are not available.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
February 28, 2021

CONSOLIDATED BALANCE SHEET (\$M) <sup>1,2</sup>		
Consolidated Results of Purdue Pharma, L.P. and all Debtors except Purdue Pharma, Inc.		
		Book Value
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Cash & Cash Equivalents	\$	981
Available For Sale Investments		35
Accounts Receivable, Net		140
Due From Associated Companies		4
Other Receivables		6
Inventories, Net		84
Prepaid Expenses & Other Current Assets		50
Restricted Cash		30
<b>TOTAL CURRENT ASSETS</b>		<b>1,330</b>
Property and Equipment, net		67
Investments at Cost		38
Restricted Cash - Long-Term		149
Intangible Assets, Net		95
Other Assets		16
<b>TOTAL ASSETS</b>	<b>\$</b>	<b>1,695</b>
<b>LIABILITIES AND EQUITY</b>		
<b>CURRENT LIABILITIES</b>		
Accounts Payable	\$	46
Accrued Expenses		290
<b>TOTAL CURRENT LIABILITIES</b>		<b>336</b>
Other Liabilities		69
Due to Associated Companies		11
Liabilities Subject to Compromise <sup>3,4</sup>		3,017
<b>TOTAL LIABILITIES</b>		<b>3,433</b>
<b>EQUITY</b>		
Retained Earnings & Partners' Capital		(1,695)
Accumulated Other Comprehensive Loss		(43)
<b>TOTAL EQUITY</b>		<b>(1,738)</b>
<b>TOTAL LIABILITIES AND EQUITY</b>	<b>\$</b>	<b>1,695</b>

**Footnotes**

1) The numbers reflected in the Consolidated Balance Sheet are shown in MILLIONS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

3) On September 15, 2019, the Company announced that it had reached an agreement in principle on a framework for settling the U.S. opioid litigation facing the Company with twenty-four (24) state attorneys general, analogous officials from five (5) U.S. territories, the Plaintiff's Executive Committee in the MDL, and co-lead counsel in the MDL. In connection with this agreement in principle, the shareholders of the Company are expected to contribute their ownership in the Company to a trust or other entity established for the benefit of claimants and the American people and a minimum of \$3.0 billion, with the potential for substantial further monetary contributions from the sales of their ex-U.S. pharmaceutical businesses. The Company has concluded that for accounting purposes a loss has been incurred and has recorded a provision in the amount of \$3.0 billion, in accordance with ASC 450, Accounting for Contingencies. This accounting provision of \$3.0 billion was recorded retroactively to December 31, 2018. The Company expects this amount to be paid by the shareholders of the Company. The Company will reclassify the liability associated with the cash settlement that is expected to be paid by the Company's shareholders to equity as a capital contribution if the settlement agreement is finalized and executed.

4) The debtors historically updated contingencies as part of their year-end review with their auditors, Ernst and Young. That process is ongoing for year ended December 31st, 2020 and as of this reporting, the Debtors have not completed their assessment of the adjustments required to accruals for settlements entered into during 2020, other claims made against the Debtors or settlement discussions that are ongoing. The Debtors, note however, that they are in active settlement discussions with various creditors to settle outstanding claims and will incorporate any settlements as appropriate when the accruals are updated. Refer to separate disclosure on Liabilities Subject to Compromise and Contingencies.

Liabilities Subject to Compromise and Contingencies

Settlement Expense recorded in 2019 Audited Financial Statements

On September 15, 2019, the Company announced that it had reached an agreement in principle on a framework for settling the U.S. opioid litigation facing the Company with twenty-four (24) state attorneys general, analogous officials from five (5) U.S. territories, the Plaintiff's Executive Committee in the MDL, and co-lead counsel in the MDL. In connection with this agreement in principle, the shareholders of the Company are expected to contribute their ownership in the Company to a trust or other entity established for the benefit of claimants and the American people and a minimum of \$3.0 billion, with the potential for substantial further monetary contributions from the sales of their ex-U.S. pharmaceutical businesses. The Company has concluded that for accounting purposes a loss has been incurred and has recorded a provision in the amount of \$3.0 billion, in accordance with ASC 450, Accounting for Contingencies. This accounting provision of \$3.0 billion was recorded retroactively to December 31, 2018. The Company expects this amount to be paid by the shareholders of the Company. The Company will reclassify the liability associated with the cash settlement that is expected to be paid by the Company's shareholders to equity as a capital contribution if the settlement agreement is finalized and executed.

Settlement Agreements Entered into in 2020

The debtors historically updated contingencies as part of their year end review with their auditors, Ernst and Young. That process is ongoing for year ended December 31<sup>st</sup>, 2020 and as of this reporting, the Debtors have not completed their assessment of the adjustments required to accruals for settlements entered into during 2020, other claims made against the Debtors or settlement discussions that are ongoing, as described below:

A. DOJ Settlement with Debtors

The United States Department of Justice (the “**DOJ**”) filed claims against the Debtors in the aggregate amount of at least \$12.5 billion relating to the Debtors’ past practices related to the production, sale, marketing and distribution of opioid products.

On October 21, 2020, the Debtors entered into (i) a plea agreement (the “**Plea Agreement**”) with the United States, acting through the United States Attorney’s Office for the District of New Jersey (the “**NJ USAO**”), the United States Attorney’s Office for the District of Vermont (the “**VT USAO**”), and the United States Department of Justice, Civil Division, Consumer Protection Branch (“**DOJ Consumer Protection**”), and (ii) a civil settlement agreement (the “**Civil Settlement Agreement**” and, together with the Plea Agreement, and including the settlements contemplated thereby and the other terms and conditions thereof, the “**DOJ Resolution**”) with the United States, acting through the United States Department of Justice, Civil Division, Commercial Litigation Branch (“**DOJ Commercial Litigation**”), NJ USAO, and VT USAO and on behalf of the Office of Inspector General of the United States Department of Health and Human Services (“**HHS-OIG**”), the Defense Health Agency, acting on behalf of the TRICARE Program, 10 U.S.C. §§ 1071-1110b (“**TRICARE**”), and the Office of Personnel Management.

Under the Plea Agreement, PPLP agreed to plead guilty to three counts as detailed in the Plea Agreement: (i) a dual-object conspiracy to defraud the United States in violation of 18 U.S.C. § 371 and to violate the Food, Drug, and Cosmetic Act in violation of 21 U.S.C. §331, 333(a)(1) and 353, all in violation of 18 U.S.C. §371, (ii) conspiracy to violate the Federal Anti-Kickback Statute related to Purdue’s payments to healthcare providers, contrary to 42 U.S.C. § 1320a-7b(b), in violation of 18 U.S.C. § 371; and (iii) conspiracy to violate the Federal Anti-Kickback Statute related to Purdue’s payments to Practice Fusion, a cloud-based EHR platform, contrary to 42 U.S.C. § 1320a-7b(b), in violation of 18 U.S.C. § 371.

The Bankruptcy Court approved the Debtors entering into the DOJ Resolution on November 17, 2020. The DOJ Resolution provides for the following:

1. a \$2 billion criminal forfeiture judgment which will be treated as an allowed superpriority administrative claim in the bankruptcy (the “**DOJ Forfeiture Judgment Claim**”);

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2021 to February 28, 2021

2. \$3.544 billion in criminal fines which will be treated as an allowed, unsubordinated, undisputed, non-contingent, liquidated general unsecured claim in the bankruptcy (the “**DOJ Criminal Fine Claim**”); and
3. a \$2.8 billion civil damages claim which is an allowed, unsubordinated, non-contingent, liquidated general unsecured claim (the “**DOJ Civil Claim**”), subject to certain rescission rights on the part of DOJ.

While the total amount of claims under the DOJ Resolution is \$8.3 billion, only the \$2.8 billion DOJ Civil Claim was allowed by the 9019 order approving the DOJ Resolution. The other two claims will become allowed upon the later of (i) the entry of a judgment of conviction by the United States District Court for the District of New Jersey (the “**District Court**”) and (ii) confirmation of a chapter 11 plan of reorganization for the Debtors (the “**Plan**”).

The timeline for plan confirmation and emergence from chapter 11 is expected to include, among other things, (1) the Debtors filing a Plan, an accompanying disclosure statement (the “**Disclosure Statement**”), a motion to approve the Disclosure Statement and solicitation and noticing procedures and materials (the “**Disclosure Statement Motion**”) and a related scheduling motion (the “**Motion for Schedule and Protocols**”), (2) entry of orders granting the Disclosure Statement Motion and Motion for Schedule and Protocols following a hearing, (3) voting on the Plan by the claimants and (4) confirmation of the Plan by the Bankruptcy Court following a hearing.

Pursuant to the Plea Agreement, the sentencing hearing in the District Court is expected to take place at least 75 days following confirmation of a Plan (and at least seven days before emergence). Prior to the sentencing hearing:

Purdue may withdraw from the Plea Agreement if: (1) the Bankruptcy Court rejects, or otherwise declines to confirm, a Plan that provides for the emergence of a public benefit company (or entity with a similar mission); or (2) the HHS-OIG exercises, or states an intent to exercise, any available authority to exclude PPLP’s successor public benefit company (or entity with a similar mission) from participation in federal healthcare programs. At the sentencing hearing, the District Court will decide whether to accept the Plea Agreement; if the District Court rejects the Plea Agreement, Purdue or DOJ may withdraw from the Plea Agreement. If the District Court accepts the Plea Agreement at the sentencing hearing, it will enter the \$2 billion forfeiture judgment and a judgment of conviction will be entered soon after the sentencing hearing.

Upon entry of the judgment of conviction, and so long as a plan of reorganization has been confirmed, then:

1. the \$2 billion DOJ Forfeiture Judgment will be treated as an allowed superpriority administrative claim in the bankruptcy; and
2. the \$3.544 billion DOJ Criminal Fine Claim will be treated as an allowed, unsubordinated, non-contingent, liquidated general unsecured claim in the bankruptcy.

Pursuant to the Plea Agreement, the United States has agreed to provide offset credit (the “**Forfeiture Judgment Credit**”) for value conferred upon the non-federal government creditors up to \$1.775 billion out of the \$2 billion DOJ Forfeiture Judgment Claim provided that the Debtors: (i) obtain confirmation of a Plan that provides that all of the Debtors’ assets are transferred to a public benefit company (or entity with a similar mission); and (ii) distribute at least \$1.775 billion of value to state, tribal, and local governments in satisfaction of their claims, with such funds to be dedicated to abatement programs. PPLP will make a \$225 million upfront payment to the United States within three business days following the entry of a judgment of conviction pursuant to the Plea Agreement. The remaining \$1.775 billion of the DOJ Forfeiture Judgment Claim is expected to be satisfied through the Forfeiture Judgment Credit.

If the Bankruptcy Court does not confirm a Plan of Reorganization in the Chapter 11 Cases that provides for the emergence from the Chapter 11 Cases of a public benefit company (or entity with a similar mission), Purdue and the United States each have the option to rescind the Civil Settlement Agreement.

#### **B. Sackler Settlement with the DOJ**

On October 20, 2020 Named Sacklers entered into an agreement with the DOJ to pay two-hundred twenty-five million (\$225,000,000) plus interest on the Settlement Amount at the rate of 0.75% from November 5, 2020 on the later of (i) fifteen (15) days after the effective date of the Agreement or (ii) three (3) business days after the date on which the Bankruptcy Court grants a Motion to Confirm (as defined in Paragraph 2). The Bankruptcy Court granted a Motion to Confirm on November 18<sup>th</sup>, 2020.

**C. Other Claims**

The Bankruptcy Court for the Southern District of New York set the deadline to file a claim against the Debtors as of July 30, 2020 (the “**Bar Date**”). With certain exceptions, persons and entities that wished to assert a claim against the Debtors that arose prior to September 15, 2019 were required to file a proof of claim before the Bar Date in order to be treated as a creditor with respect to such claim for purposes of voting and distribution. Over 619,000 claims were submitted in advance of the Bar Date, with an asserted value of over of \$140 trillion.

The Company is in the process of reviewing, analyzing, and reconciling filed claims, and at present, the allowed amounts of such claims are not determinable. The Company expects the claims resolution process will take significant time to complete. As the amounts of the allowed claims are determined, adjustments will be recorded to liabilities subject to compromise and reorganization expenses due to bankruptcy.

**D. Ongoing Settlement Discussions with Sacklers**

As noted above, the Debtors recorded a provision of \$3.0 billion representing the minimum contribution from the shareholders, which is included as a liability subject to compromise as a retroactive adjustment to December 31, 2018. On March 15, 2021, Purdue filed a Plan of Reorganization in the U.S. Bankruptcy Court. Under the Plan, the Sackler families have agreed to pay \$4.275 billion in addition to the \$225 million Sackler Settlement with the DOJ, for a total settlement of \$4.5 billion. The \$4.5 billion represents a \$1.5 billion increase from the \$3 billion agreement in principle reached in September 2019, previously recorded as a liability subject to compromise. The Debtors are working with their auditors, Ernst and Young to consider the increase in loss that will need to be recognized. The settlement amount will be paid by the shareholders of the Company. The Company will reclassify the totality of the ultimate liability recorded, to equity as a capital contribution when a settlement agreement is finalized and executed.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
February 28, 2021

**PURDUE PHARMA, INC. BALANCE SHEET (\$000) <sup>1,2</sup>**

	<b>Book Value</b>
<b>Assets</b>	
Currents assets:	
Cash and cash equivalents	\$ 1,250
Prepaid expenses	281
Due from Associated Companies	135
<b>Total current assets</b>	<b>1,666</b>
Investments	10,267
<b>Total assets</b>	<b>\$ 11,933</b>
<b>Liabilities and equity</b>	
Current liabilities:	
Accounts payable	\$ 463
Due to Associated Companies	183
Accrued Expenses	178
<b>Total liabilites</b>	<b>824</b>
Common stock	1
Additional paid-in capital	499
Retained earnings	10,674
Accumulated other comprehensive loss	(65)
<b>Total equity</b>	<b>11,109</b>
<b>Total liabilites and equity</b>	<b>\$ 11,933</b>

**Footnotes**

1) The numbers reflected in the Consolidated Balance Sheet are shown in THOUSANDS.

2) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary, unaudited, and subject to change.

**In re: PURDUE PHARMA L.P., et al.,**  
**Debtors**

**Case No.: 19-23649 (RDD)**  
**Reporting Period February 1, 2021 to February 28, 2021**

**SCHEDULE OF POST PETITION TAXES**

Office of the U. S. Trustee

Re: Monthly Operating Report Attestation Regarding Post Petition Taxes

The Debtor, PURDUE PHARMA L.P. and its affiliate Debtors hereby submit this attestation regarding post petition taxes.

All post petition taxes, which are not subject to dispute or reconciliation, are current. There are no material disputes or reconciliations.

J. R. house

Signature

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2021 to February 28, 2021

SCHEDULE OF PAYMENTS TO INSIDERS (\$)

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1</sup>
<b>Compensation</b>		
Chomiak, Caroline	\$ -	\$ 261,662
Kesselman, Marc L <sup>2</sup>	173,486	7,998,698
Landau, Craig J	245,746	6,595,188
Lowne, Jonathan R	86,043	2,819,864
Lundie, David R	68,638	2,230,434
Mancinelli II, Vincent F	42,135	1,292,501
Mazzi, Christian	-	439,030
Medeiros, Paul	-	1,280,482
Shamblen, Randy	35,654	1,295,943
Strassburger, Philip C	-	1,614,331
<b>Total Compensation</b>	<b>651,702</b>	<b>25,828,134</b>
<b>Director Fees</b>		
Boer, F Peter	-	1,050,000
Buckfire, Kenneth A	-	1,050,000
Cola, Michael	-	1,050,000
Collins, Michael J	-	25,000
Dubel, John	-	1,050,000
Miller, Robert S	208,333	3,333,333
Muhlhauser, Eckhard	-	25,000
Pickett, Cecil	-	1,050,000
<b>Total Director Fees</b>	<b>208,333</b>	<b>8,633,333</b>
<b>T&amp;E Reimbursements</b>		
Boer, F Peter	-	10,907
Buckfire, Kenneth A	-	1,565
Chomiak, Caroline	-	30,408
Cola, Michael	-	1,388
Debone, Louis	-	1,245
Dubel, John	-	4,714
Kesselman, Marc L	101	52,281
Landau, Craig J	1,144	83,486
Lowne, Jonathan R	140	2,184
Lundie, David R	-	29,997
Mancinelli II, Vincent F	39	44,852
Mazzi, Christian	-	3,734
Medeiros, Paul	-	38,687
Miller, Robert S	-	10,315
Pickett, Cecil	-	1,298
Shamblen, Randy	-	11,738
Strassburger, Philip C	-	16,150
<b>Total T&amp;E Reimbursements</b>	<b>1,425</b>	<b>344,948</b>
<b>Housing Payments</b>		
Kesselman, Marc L	4,673	88,755
<b>Total Housing Payments</b>	<b>4,673</b>	<b>88,755</b>

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2021 to February 28, 2021

SCHEDULE OF PAYMENTS TO INSIDERS (\$)

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1</sup>
<b><i>Indemnification Payments</i></b>		
Baker, Stuart D <sup>3</sup>	39,132	1,608,010
Butcher, James A	-	527
Friedman, Michael	-	209,618
Landau, Craig J	247,047	3,770,802
Lundie, David R	574	50,458
Motahari, Saeed	-	24,680
Roncalli, Anthony	-	780,679
Stewart, John	-	255,309
Strassburger, Philip	1,822	46,935
Timney, Mark	7,563	1,507,194
Purdue Pharma Inc Independent Directors <sup>4</sup>	18,296	1,914,503
<b>Total Indemnification Payments</b>	<b>314,434</b>	<b>10,168,714</b>
<b><i>Payments to Independent Associated Companies</i></b>		
Mundibiopharma Ltd	-	55,332
Mundipharma DC BV	-	294,253
Mundipharma International Ltd	-	11,053
Mundipharma International Technical Operations Ltd	4,396	21,782
Mundipharma IT Services Ltd	-	278,603
Mundipharma Laboratories GmbH	-	1,590,148
Mundipharma Research Ltd	-	113,807
Mundipharma Singapore Holdings Pte Ltd	-	60,675
One Stamford Realty L.P.	474,504	15,682,927
Pharmaceutical Research Associates Inc.	566,308	2,115,952
Purdue Pharma Canada	125,895	5,403,822
Purdue Pharma Technologies Inc.	-	26,350
Terramar Foundation	-	1,000
TXP Services Inc. <sup>5</sup>	58,333	6,926,365
<b>Total Payments to Independent Associated Companies</b>	<b>1,229,437</b>	<b>32,582,069</b>
<b>Total Payments to Insiders</b>	<b>\$ 2,410,003</b>	<b>\$ 77,645,953</b>

**Footnotes**

1) Represents payments made since the Commencement Date.

2) Automobile allowance for Marc L. Kesselman is partially received in cash and partially through personal usage of a company-owned vehicle.

3) Indemnification payments made in June 2020 on behalf of Stuart D. Baker were inadvertently in amounts exceeding the 50% reimbursement rate approved by the Special Committee of Purdue Pharma Inc.'s Board of Directors, totaling \$12,390. Overpayments are in the process of being reversed through future invoice credits, repayment from respective law firms, and/or reimbursement from Stuart D. Baker. Currently, \$6,158.05 of this total remains outstanding.

4) These indemnification payments relate to litigation in which the following current and former Independent Directors of Purdue Pharma Inc. are all listed as defendants: Boer, F Peter; Costa, Paolo; Lewent, Judy; Pickett, Cecil; and Snydeman, Ralph.

5) Payments to TXP include a monthly charge of approximately \$58,333 for Anthony Roncalli's service as a Director for Purdue Pharma Inc.

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2021 to February 28, 2021

SCHEDULE OF RETAINED RESTRUCTURING PROFESSIONAL FEES (\$)

NAME	AMOUNT PAID DURING THE REPORTING PERIOD	CUMULATIVE <sup>1,2</sup>
<i>Estate Professionals</i>		
Davis Polk & Wardwell LLP	\$ 11,735,870	\$ 92,625,758
AlixPartners, LLP	534,332	17,170,779
PJT Partners LP	-	2,983,455
Ernst & Young	-	1,231,000
Cornerstone Research	698,264	2,976,996
Prime Clerk LLC	1,180,190	54,101,777
<b>Total Estate Professionals</b>	<b>14,148,655</b>	<b>171,089,765</b>
<i>Creditor Committee Professionals</i>		
Akin Gump Strauss Hauer & Feld LLP	4,051,824	60,807,065
Bayard, P.A.	-	1,170,655
Cole Schotz P.C.	1,044,717	12,704,926
Jefferies LLC	367,788	3,212,608
KPMG	-	3,269,195
Province, Inc.	774,175	18,234,017
Kurtzman Carson Consultants LLC	-	529,890
Bedell Cristin	34,670	237,349
<b>Total Creditor Committee Professionals</b>	<b>6,273,174</b>	<b>100,165,705</b>
<i>Ad Hoc Committee Professionals</i>		
Kramer Levin Naftalis & Frankel LLP	693,717	8,539,892
Brown Rudnick LLP	-	4,382,308
Gilbert LLP	224,682	4,751,542
Otterbourg PC	-	2,006,292
FTI Consulting, Inc	-	6,537,990
Houlihan Lokey	480,813	2,308,568
Compass Lexecon	-	-
Coulter & Justice	-	-
<b>Total Ad Hoc Committee Professionals</b>	<b>1,399,212</b>	<b>28,526,592</b>
<i>Special Counsel to the Debtors</i>		
Arnold Porter & Kaye Scholer	146,215	1,847,614
Dechert LLP	0	5,710,073
Jones Day	-	2,632,616
King & Spalding LLP	-	18,060,242
Skadden, Arps, Slate, Meagher & Flom LLP	965,251	19,324,869
Wilmer Cutler Pickering Hale and Dorr LLP	-	801,747
<b>Total Special Counsel Professionals</b>	<b>1,111,466</b>	<b>48,377,160</b>
<i>The Law Offices of Kenneth Feinberg (Mediator)</i>		
Phillips ADR (Mediator)	-	5,502,648
Bielli & Klauder, LLC (Fee Examiner)	-	5,504,089
Tom Vilsack (Court appointed monitor)	-	391,375
Ernst & Young (Canada), Court Appointed Information Officer	-	190,650
<b>Total Retained Restructuring Professional Fees</b>	<b>\$ 22,932,507</b>	<b>\$ 359,961,939</b>

**Footnotes**

1) Represents payments made since the Commencement Date

2) Prior periods may have been corrected to include payments erroneously omitted in earlier reports

In re: PURDUE PHARMA L.P., et al.,  
Debtors

Case No.: 19-23649 (RDD)  
Reporting Period February 1, 2021 to February 28, 2021

DEBTOR QUESTIONNAIRE

Must be completed each month. If the answer to any of the questions is "Yes", provide a detailed explanation of each item. Attach additional sheets if necessary.	Yes	No	Comments
Have any assets been sold or transferred outside the normal course of business this reporting period?		X	
Have any funds been disbursed from any account other than a debtor in possession account this reporting period?		X	
Is the Debtor delinquent in the timely filing of any post-petition tax returns?		X	
Are workers compensation, general liability or other necessary insurance coverages expired or cancelled, or has the debtor received notice of expiration or cancellation of such policies?		X	
Is the Debtor delinquent in paying any insurance premium payment?		X	
Have any payments been made on pre-petition liabilities this reporting period?	X		Payments made pursuant to certain First Day Orders were made during the period.
Are any post petition receivables (accounts, notes or loans) due from related parties?	X		Purdue Pharma, LP receives royalties from affiliated entities for foreign sales of certain products.
Are any post petition payroll taxes past due?		X	
Are any post petition State or Federal income taxes past due?		X	
Are any post petition real estate taxes past due?		X	
Are any other post petition taxes past due?		X	
Have any pre-petition taxes been paid during this reporting period?		X	
Are any amounts owed to post petition creditors delinquent?		X	
Are any wage payments past due?		X	
Have any post petition loans been received by the Debtor from any party?		X	
Is the Debtor delinquent in paying any U.S. Trustee fees?		X	
Is the Debtor delinquent with any court ordered payments to attorneys or other professionals?		X	
Have the owners or shareholders received any compensation outside of the normal course of business?		X	